Skip to Content

Conivaptan Disease Interactions

There are 4 disease interactions with conivaptan:


Conivaptan (Includes Conivaptan) ↔ Heart Failure

Moderate Potential Hazard, Moderate plausibility

Applies to: Congestive Heart Failure

The amount of safety data on the use of conivaptan in patients with hypervolemic hyponatremia associated with heart failure is limited. Conivaptan should only be used to raise sodium in such patients after consideration of other treatment options. Caution is advised if using in these patients.


Conivaptan (Includes Conivaptan) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The systemic exposure to unbound conivaptan doubled in subjects with moderate and severe hepatic impairment. Caution is advised in these patients.


Conivaptan (Includes Conivaptan) ↔ Severe Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The use of conivaptan is not recommended in patients with severe renal impairment (CrCl < 30 mL/min), as there is an unlikely benefit. There is also a high incidence of infusion site phlebitis, which can reduce vascular access sites.


Vasopressin Antagonists (Includes Conivaptan) ↔ Liver Disease/Alcoholism

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Alcoholism

Osmotic demyelination syndrome is a risk associated with overly rapid correction of hyponatremia (> 12 mEq/L/24 hours). This syndrome can result in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizure, coma or death. Patients with advanced liver disease, alcoholism or severe malnutrition are at increased risk and require slower rates of correction. Serum sodium concentration and neurological status should be monitored appropriately during treatment administration. Vasopressin antagonists should be initiated and re- initiated in patients only in hospital settings were sodium levels can be monitored closely.

conivaptan drug Interactions

There are 463 drug interactions with conivaptan

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.